Clinical trials: Primary-progressive Multiple Sclerosis
Multiple Sclerosis, Depression - Major Depressive Disorder
Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis
Canada has one of the highest rates of multiple sclerosis (MS). MS patients experience disabling motor, visual, and sensory symptoms, and a high risk of comorbid major depressive disorder (MDD) and severe fatigue.
- Conditions
- Multiple Sclerosis, Depression - Major Depressive Disorder, Fatigue
- Trial name
- NCT07562074
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive
Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients
Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant.
- Trial name
- NCT04550650
- Testing
- Training groupe, PNF, Spinning grp
- Where
- Hungary
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital
Multiple Sclerosis, Primary Progressive, Cognitive Impairment
Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation
Given that up to 70% of people with secondary progressive MS are cognitively impaired, the search for effective treatments is considered a priority by people living with the disease.
- Trial name
- NCT03679468
- Testing
- Cognitive Rehabilitation, Aerobic Exercise
- Where
- Canada
- Volunteers
- 309 people
- Sponsor
- Sunnybrook Health Sciences Centre
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
The purpose of the study is to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously administered MIS416 weekly in patients with chronic…
- Trial name
- NCT01191996
- Testing
- MIS416
- Where
- New Zealand
- Volunteers
- 34 people
- Sponsor
- Innate Immunotherapeutics
Primary Progressive Multiple Sclerosis
Tear Analysis in the Diagnosis of Multiple Sclerosis
In the primary progressive multiple sclerosis, the detection of oligoclonal bands in cerebrospinal fluid is critical for the diagnosis.
- Trial name
- LARMES (NCT02016222)
- Testing
- tears sampling
- Where
- 13 sites in France
- Volunteers
- 80 people
- Sponsor
- Lille Catholic University
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with…
- Trial name
- NCT01982942
- Testing
- ibudilast
- Where
- 28 sites in United States
- Volunteers
- 255 people
- Sponsor
- MediciNova
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis
MUSCLE - Nordic Walking in MUltiple SCLErosis
The aim of the study is to analyze the effects of Nordic Walking and free walking in the clinical-functional, postural balance, motor control, muscular echographic quality, and gait analysis (pendulum gait mechanism), in people…
- Conditions
- Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MUSCLE (NCT05385731)
- Testing
- Nordic Walking (NWG), Free Walking (FWG), Health Education (HEG)
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Leonardo A. Peyré-Tartaruga
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of…
- Trial name
- EMBOLD (NCT03283826)
- Testing
- ATA188
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- Atara Biotherapeutics
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
This clinical trial aims to demonstrate that metformin can prevent clinical disability in patients with progressive MS by stopping or slowing down neurodegeneration by enhancing endogenous remyelination.
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
- Trial name
- NCT05893225
- Testing
- Metformin Hydrochloride 850 mg Oral Tablet
- Where
- 5 sites in Belgium
- Volunteers
- 120 people
- Sponsor
- University Hospital, Antwerp
Multiple Sclerosis
Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
In this study, we propose, for the first time, to test the safety and the potential efficacy of repeated allogenic Adipose tissue-derived Mesenchymal Stromal Cells IT injections in Primary Progressive Multiple Sclerosis patients.
- Trial name
- MAESTRO-4MS (NCT06592703)
- Testing
- Adipose tissue-derived Mesenchymal Stromal Cells
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Rennes University Hospital
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Open-label Study of Liothyronine in MS
This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- NCT02506751
- Testing
- liothyronine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Primary Progressive Multiple Sclerosis, Hemiparesis
Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis
Participants will receive intensive therapy through a video game in their own homes for 1 month. The game is operated by movements of the body (no controller needed) and acts like a virtual therapist.
- Trial name
- NCT03094364
- Testing
- Gaming CI Therapy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Massachusetts, Lowell
Multiple Sclerosis
Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis
The goal of this interventional non-pharmacological study is to evaluate the involvement of the autonomic nervous system in patients with relapsing-remitting and primary progressive multiple sclerosis.
- Trial name
- NCT05748015
- Testing
- quantification of sensory and autonomic small nerve fibers by punch skin biopsy, Cardiovascular Reflexes testing, Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
This is a multicenter study conducted in 3 parts. Part A is a double-blind placebo-controlled parallel-group period, and Part B and C are open-label extension periods.
- Conditions
- Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- MOTION - JAPAN (NCT01917019)
- Testing
- BIIB041 (fampridine)
- Where
- 19 sites in Japan
- Volunteers
- 101 people
- Sponsor
- Biogen
Multiple Sclerosis
PET Study in Multiple Sclerosis
While both conventional and advanced MRI techniques offer important insights into MS pathophysiology, important aspects of this inflammatory disorder are undetectable with existing MRI technology.
- Trial name
- NCT03787446
- Where
- Canada
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Multiple Sclerosis (Primary or Secondary Progressive Phase).
The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis
In a double-blind, placebo-controlled, parallel group trial, recombinant human erythropoietin (rhEPO) (48000 IU) treatment or placebo will be administered weekly i.v. for 24 weeks: weekly for 12 weeks and bi-weekly for 12 weeks.
- Trial name
- EPO-ProgMS (NCT01144117)
- Testing
- Erythropoietin
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Primary Progressive Multiple Sclerosis
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.
- Trial name
- ORATORIO-CP (NCT05974852)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 732 people
- Sponsor
- State University of New York at Buffalo
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS.
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- IMPACT-MS (NCT07477639)
- Testing
- TRX319, Bendamustine
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis.
- Conditions
- Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
- Trial name
- NCT01466114
- Testing
- estriol, Norethindrone
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
Multiple sclerosis (MS) is a chronic inflammatory disorder affecting the central nervous system that is characterized pathologically by focal demyelinating lesions in the brain parenchyma.
- Trial name
- NCT02253264
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University